Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)
COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTREAT® in patients with aggressive brain cancer (glioblastoma). A preliminary readout of the...
COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTREAT® in patients with aggressive brain cancer (glioblastoma). A preliminary readout of the...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.